0 Items
Select Page

Hepatitis A

Hepatitis A is a liver disease caused by the hepatitis A virus. The virus is primarily spread when an uninfected (and unvaccinated) person ingests food or water that is contaminated with the faeces of an infected person. The spread of disease is closely linked to unsafe water and food, or inadequate sanitation and poor personal hygiene. Unlike hepatitis B and C, hepatitis A infection does not cause chronic liver disease and is rarely fatal, but can cause debilitating symptoms and fulminant hepatitis (acute liver failure), which is often fatal.

The Native Antigen Company offer a panel of monoclonal antibodies specific to the hepatitis A virus, to facilitate research and assay development.

Hepatitis A Background

Hepatitis A virus (HAV) is a non-enveloped, positive-sense, single stranded RNA virus and member of the Hepatovirus genus of the family Picornaviridae. One serotype and six genotypes, I to VI, of HAV have been defined. Genotypes I, II and III are known to infect humans and are further divided into subtypes A and B. Infection with any of these subtypes provides an individual with lifelong immunity against all HAV viruses that affect humans.

Humans are a natural reservoir for hepatitis A virus. Transmission of occurs primarily via the oral-faecal route through ingestion of HAV contaminated food and water, or through direct contact with an individual infected with HAV. In developing countries, Hepatitis A virus infection commonly occurs in children and is associated with poor sanitation and low socio-economic status. In developed countries, cases of HAV infection may occur in young adults that are in high-risk groups such as care workers, people who inject drugs and individuals travelling from HAV endemic countries.

HAV is thermostable and resistant to treatment with acids, ethers and disinfectants. The hepatitis A virus infects the liver and replicates in hepatocytes, causing liver inflammation. During the incubation stage of HAV infection, an infected individual may be asymptomatic, but virus particles are actively shed and can be present in the patient’s stools. A range of non-specific clinical symptoms may then develop, which include nausea, vomiting, joint pain, malaise, fatigue and fever. Additional symptoms that can occur include cough, pharyngitis, itchiness and hives. As the infection develops, the patient becomes jaundiced and, in some cases, hepatomegaly occurs. The mortality rate associated with HAV infection is low, but complications can lead to acute liver failure and death in a small percentage of cases. Although effective vaccines for the prevention of HAV infection are available, there is currently no specific treatment for patients infected with HAV (WHO).

References

  1. World Health Organization: Hepatitis A, key facts
  2. Hepatitis A Antibodies

Hepatitis A Antibodies

The Native Antigen company offers a range of monoclonal antibodies specific to the hepatitis A virus, offering a panel suitable for the development of immunoassays. These include a Hepatitis A antibody specific to the VP3 capsid polypeptide antigen, which has been shown to have neutralising activity.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

10 + 1 =

Live Customer Feedback

Join our mailing list

* indicates required